Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Apple Turns 50: From Garage Startup to AI Crossroads 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
PLAINSBORO, N.J., Dec. 19, 2016 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it will present at the following conference in January:
- At 2:30PM PT on Wednesday, January 11, 2017, Mr. Peter Arduini, President and CEO will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. This presentation will be webcast.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions and orthopedics and tissue technologies. For more information, please visit www.integralife.com
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Angela Steinway (609) 936-2268 [email protected] Michael Beaulieu (609) 750-2827 [email protected]
